Cannabis Best Opportunity Stocks $0.10 to $0.75

[greenwillow]

EHVVF - Check out their partnerships...

$EHVVF - Ehave Inc. Providing Value with Key Partnerships.

Ehave Advances MedReleaf Collaboration with Launch of Digital Patient Intake Portal TORONTO, Nov. 1, 2017



https://web.tmxmoney.com/article.php?newsid=6090817082330319&qm_symbol=LEAF

Ehave say about partnership with MedReleaf...

Ehave's technology will be integrating with MedReleaf's patient and physician dashboard that is used to establish baseline patient assessments and track patient-reported symptoms by incorporating a broad panel of clinically-validated surveys into a single digital portal. "The core of our business is focused on improving outcomes for our patients and using advanced data-driven technology to support and validate efficacy in cannabis-based medicine," says Neil Closner, CEO of MedReleaf. This first tool will be integrated with future compliance and reporting offerings co-developed by Ehave and MedReleaf that will empower patients in their treatment plans, help both patients and healthcare practitioners to encourage treatment compliance, and verify treatment outcomes in a reliable and objective manner.

"We're pleased to advance our flagship collaboration with MedReleaf and launch this first product offering for the investigation of cannabis-based therapies," said Prateek Dwivedi, CEO of Ehave. "Our core data management technology allows us to incorporate and centralize any number of validated or novel patient assessments and surveys into various formats such as our Ehave Connect clinician portal, customized Apps, engaging video games, and other digital platforms. The true power of our technology is in our ability to objectively capture patient outcomes in response to therapy, irrespective of the specific condition, format, or therapy. This provides a pathway to clinical validation for emerging treatment modalities such as medical cannabis, where efficacious dosing and administration remains to be established by clinician and regulatory standards."

Revive Therapeutics and Ehave Enter Into Patient Research Data Collaboration Agreement for Medical Cannabis Liver Disease ProgramPress Release | 03/01/2018



https://www.otcmarkets.com/stock/RVVTF/news/Revive-Therapeutics-and-Ehave-Enter-Into-Patient-Research-Data-Collaboration-Agreement-for-Medical-Cannabis-Liver-Diseas?id=184803

Revive Therapeutics Ltd.says...

“We are very excited with our collaboration with Ehave as it provides us with a foundation of employing next generation patient and clinical research data management solutions early on in the research and development phase of our liver disease program,” said Craig Leon, Chief Executive Officer of Revive. “Ehave’s Platform will support our research and clinical decisions and it will allow us to make objective, data-driven decisions throughout the course of our research and may provide unique insights to expand our initiatives with cannabinoids for the potential treatment of liver diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and fibrosis.”

Ehave's Bioinformatics Platform Technology to Be Used to Evaluate Aequus' Products in Multiple Neurological Disorders Press Release | 03/05/2018



https://www.otcmarkets.com/stock/AQSZF/news/Aequus-and-Ehave-Enter-Into-Collaboration-Agreement-for-Comprehensive-Patient-Data-Management-in-Clinical-Trials-of-Medi?id=185143

Aequus says...

"Our thinking regarding conducting clinical trials of various cannabinoid containing formulations has advanced substantially since we signed the original Letter of Intent with Ehave. We have a number of different trials in late-stage planning and see multiple opportunities for us to leverage our traditional pharmaceutical expertise in designing and implementing clinical programs, but we also see growing opportunities for us to leverage our existing relationships with Canadian clinicians and take advantage of our existing pharmaceutical sales infrastructure to better serve clinicians and Insurers as it relates to medical cannabis. We and Ehave are in a unique position to generate meaningful product safety and efficacy data in a variety of trial settings in a very efficient and cost-effective way," says Doug Janzen, Chairman and CEO of Aequus. "In our most recent comprehensive physician survey regarding factors that prevent them from recommending medical cannabis products, Canadian clinicians identified the lack of robust clinical data in a real-world setting for such products as a significant limiting factor."